cagrilintide/semaglutide New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Cagrilintide–Semaglutide in Adults with Overweight

(2017) Cardiovascular safety and benefits of GLP-1 receptor agonists

Density and wrinkle changes appear at 8 to 12 weeks

These are not comparable treatments

Dealing with Persistent Flushing Comprehensive Flushing Protocol: Week 1: Reduce BPC-157 to 200 mcg once daily Inject at bedtime Take 10 mg cetirizine (Zyrtec) 30 minutes before injection Ensure well hydrated (64+ oz water daily) Week 2: If flushing resolved, maintain current protocol If persisting, drop to 150 mcg daily Add 500 mg niacinamide (not niacin) daily to support vascular stability Week 3: If still flushing, switch to intramuscular administration Consider alternating days instead of daily Evaluate peptide source quality Week 4+: If flushing still problematic, discontinue and try TB-500 instead Or switch to topical BPC-157 formulations for localized applications Addressing Injection Site Issues Nodule Resolution Protocol: For persistent subcutaneous lumps: Stop injecting affected area completely for 2 to 4 weeks Gentle massage 2 to 3 times daily with moisturizer or oil Warm compress 10 to 15 minutes twice daily Topical DMSO (dimethyl sulfoxide) may help dissolve deposits (research controversial) Evaluate technique and adjust depth, speed, volume Consider IM administration to avoid subcutaneous depot formation If nodules persist beyond 4 weeks, grow, become painful, or show infection signs, seek medical evaluation